EryDex study for rare nerve disorder ends early, but offers continued treatment access
Disease control
Terminated
This study aimed to give continued access to the experimental drug EryDex for people with ataxia telangiectasia, a rare genetic disease that affects coordination and the immune system. It enrolled 101 patients who had already completed a previous EryDex trial. The main goal was t…
Phase: PHASE3 • Sponsor: Quince Therapeutics S.p.A. • Aim: Disease control
Last updated May 26, 2026 18:16 UTC